Blackhall F - Search Results

1

Selumetinib in the treatment of non-small-cell lung cancer.

Bernabé R, Patrao A, Carter L, Blackhall F, Dean E. Bernabé R, et al. Among authors: blackhall f. Future Oncol. 2016 Nov;12(22):2545-2560. doi: 10.2217/fon-2016-0132. Epub 2016 Jul 28. Future Oncol. 2016. PMID: 27467210 Review.

2

Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.

Blackhall FH, Shepherd FA. Blackhall FH, et al. Hematol Oncol Clin North Am. 2004 Oct;18(5):1121-41, ix. doi: 10.1016/j.hoc.2004.06.005. Hematol Oncol Clin North Am. 2004. PMID: 15474338 Review.

3

Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.

Blackhall FH, Bhosle J, Thatcher N. Blackhall FH, et al. Curr Opin Oncol. 2005 Mar;17(2):135-9. doi: 10.1097/01.cco.0000152629.20996.9e. Curr Opin Oncol. 2005. PMID: 15725918 Review.

4

Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?

Blackhall FH, Shepherd FA, Albain KS. Blackhall FH, et al. Treat Respir Med. 2005;4(2):71-84. doi: 10.2165/00151829-200504020-00001. Treat Respir Med. 2005. PMID: 15813659 Review.

5

Erlotinib in non-small cell lung cancer: a review.

Blackhall FH, Rehman S, Thatcher N. Blackhall FH, et al. Expert Opin Pharmacother. 2005 Jun;6(6):995-1002. doi: 10.1517/14656566.6.6.995. Expert Opin Pharmacother. 2005. PMID: 15952927 Review.

6

Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.

Thatcher N, Faivre-Finn C, Blackhall F, Anderson H, Lorigan P. Thatcher N, et al. Among authors: blackhall f. Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5051s-5056s. doi: 10.1158/1078-0432.CCR-05-9004. Clin Cancer Res. 2005. PMID: 16000613 Free article. Review.

7

Where next for gefitinib in patients with lung cancer?

Blackhall F, Ranson M, Thatcher N. Blackhall F, et al. Lancet Oncol. 2006 Jun;7(6):499-507. doi: 10.1016/S1470-2045(06)70725-2. Lancet Oncol. 2006. PMID: 16750500 Review.

8

Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.

Baka S, Manegold C, Buchholz E, Schott-von-Römer K, Lorigan P, Nagel S, Blackhall F, Aschroft L, Thatcher N. Baka S, et al. Among authors: blackhall f. Lung Cancer. 2006 Aug;53(2):165-70. doi: 10.1016/j.lungcan.2006.04.010. Epub 2006 Jun 19. Lung Cancer. 2006. PMID: 16787686

9

Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic.

Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Dean EJ, et al. Among authors: blackhall f. Cancer Treat Rev. 2007 Apr;33(2):203-12. doi: 10.1016/j.ctrv.2006.11.002. Epub 2007 Jan 8. Cancer Treat Rev. 2007. PMID: 17210228 Review.

10

Small cell lung cancer and targeted therapies.

Blackhall FH, Shepherd FA. Blackhall FH, et al. Curr Opin Oncol. 2007 Mar;19(2):103-8. doi: 10.1097/CCO.0b013e328011bec3. Curr Opin Oncol. 2007. PMID: 17272981 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters